Ranbaxy signs licence deal with S. Korean firm Forbes Ranbaxy will launch Medy-Tox's anti-ageing medicine Neuronox in India to boost its presence in the dermatological segment, said a company statement. |
Ranbaxy signs licence deal with S. Korean firm Forbes Ranbaxy will launch Medy-Tox's anti-ageing medicine Neuronox in India to boost its presence in the dermatological segment, said a company statement. |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.